SB
GALT icon

SIG Brokerage’s Galectin Therapeutics GALT Stock Holding History

SIG Brokerage’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.1K Hold
13,596
– – ﹤0.01% 893
2026
Q1 		$37.9K Hold
13,596
– – ﹤0.01% 761
2025
Q4 		$56.6K Sell
13,596
-2,121
-13% -$11.2K ﹤0.01% 647
2025
Q3 		$66.6K Sell
15,717
-3,783
-19% -$14.2K ﹤0.01% 716
2025
Q2 		$41.1K Hold
19,500
– – ﹤0.01% 671
2025
Q1 		$23.8K Buy
+19,500
New +$27.4K ﹤0.01% 525

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SIG Brokerage's GALT Position: Q2 2026 in Review

SIG Brokerage held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 13,596 shares worth $63.1K. The position accounts for ﹤0.01% of the portfolio, ranked #893.

SIG Brokerage first reported a position in GALT in Q1 2025 and has held it in 6 quarters since. The position peaked at $66.6K in Q3 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • SIG Brokerage held 13,596 shares of Galectin Therapeutics worth $63.1K as of Q2 2026.
  • SIG Brokerage left its Galectin Therapeutics share count unchanged in Q2 2026.
  • Galectin Therapeutics made up ﹤0.01% of SIG Brokerage's portfolio in Q2 2026, its #893 holding.
  • SIG Brokerage first reported a position in Galectin Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • SIG Brokerage's Galectin Therapeutics position peaked at $66.6K in Q3 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on SIG Brokerage's 13F filing for Q2 2026, filed 14 Aug 2026.